On October 15, 2025, CME Group and FTSE Russell announced a 12‑year extension of their exclusive license to offer futures, options on futures and OTC‑cleared products based on FTSE Russell indexes. The extension, effective through 2037, was announced by both parties at 10:30 ET on the same day.
The license covers a broad range of equity index products, including futures on the Russell 1000 and Russell 2000, their growth and value variants, the FTSE Emerging Market, FTSE Developed Europe, FTSE China 50, and the FTSE CoreCommodity CRB indexes. Under the previous agreement, more than 573 million FTSE Russell index‑related futures and options on futures contracts had traded, and the year‑to‑date average daily volume across the Russell futures and options complex stood at 306,000 contracts.
By securing this long‑term partnership, CME Group maintains and expands its presence in the equity index derivatives market, ensuring continued liquidity and revenue generation from a wide array of index products. The extension reinforces CME’s competitive position and supports its strategy of offering deep, liquid markets for institutional and retail participants.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.